GlassScriptPhysician profile
Tammy L Osborn
NPI 1184996019
$7,874.31
in general payments reported to CMS, 2019-2025
51 companies · $1,742 in 2025
The $1,742 reported for 2025 was more than what 92% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,258 · 2022: $1,352 · 2023: $1,785 · 2024: $1,738 · 2025: $1,742.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,202 · Education: $61.57.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,202.37 |
| Education | $61.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,685.88 | 2021-2025 | |
| Lilly USA, LLC | $1,023.45 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $665.88 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $540.83 | 2021-2025 | Airsupra, Farxiga, Breztri |
| Merck Sharp & Dohme LLC | $384.88 | 2021-2024 | Belsomra, Steglatro, Capvaxive |
| Bayer Healthcare Pharmaceuticals INC. | $327.04 | 2022-2025 | |
| Abbott Laboratories | $279.65 | 2022-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Novartis Pharmaceuticals Corporation | $256.56 | 2021-2025 | |
| Amgen INC. | $247.73 | 2021-2024 | Evenity, Prolia, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $192.68 | 2021-2024 | Jardiance, Synjardy, Tradjenta |
| Glaxosmithkline, LLC. | $190.13 | 2021-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Astellas Pharma US INC | $154.85 | 2023-2025 | Veozah, Myrbetriq |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $144.88 | 2023-2025 | Caplyta |
| Cequr Corporation | $140.29 | 2023-2024 | Cequr Simplicity |
| Otsuka America Pharmaceutical, INC. | $134.69 | 2021-2025 | Rexulti |
Show all 51 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tammy Osborn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.